DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on February 10, 2006; DOI: 10.1124/dmd.105.008722

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.008722v1
34/5/800    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tenmizu, D.
Right arrow Articles by Sawada, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tenmizu, D.
Right arrow Articles by Sawada, Y.


Received for publication December 2, 2005.
Revised February 2, 2006.
Accepted for publication February 3, 2006.

The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of YM-64227, a phosphodiesterase type 4 inhibitor

Daisuke Tenmizu 1*, Kiyoshi Noguchi 1, Hidetaka Kamimura 1, Hisakazu Ohtani 2, Yasufumi Sawada 2

1 Astellas Pharmaceutical Inc 2 Tokyo University

* Address correspondence to: E-mail: daisuke.tenmizu{at}jp.astellas.com

Abstract

In a previous study, it was shown that the novel canine SNP CYP1A2 1117C>T yields an inactive enzyme. In this study, the effect that this SNP has on the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1H)-one (YM-64227) was investigated. Plasma concentrations of the unchanged drug and five of its metabolites (MM-1 to MM-5) were determined after either intravenous or oral administration of YM-64227 to genotyped dogs (C/C, C/T, and T/T groups). Liver microsomes were prepared from these dogs to determine the in vitro metabolic clearance of YM-64227. After a single oral administration, the maximum plasma concentration and absolute bioavailability of YM-64227 in the T/T group were 17.1 times and 27.2 times higher than those in the C/C group, respectively, while the pharmacokinetics of YM-64227 after intravenous administration were not affected by genotype. The metabolic profiles in the T/T group were quite distinct from the others, i.e., the main metabolite was MM-2 in the C/C group, while MM-1 and MM-5 were main metabolites in the T/T group. The formation clearances of MM-2 and MM-3 in the microsomes derived from T/T type dogs were significantly lower, whereas those of MM-1, MM-4, and MM-5 were not affected. A statistically significant correlation was observed between the in vivo and in vitro metabolic intrinsic clearances (r = 0.82, p < 0.001). The canine CYP1A2 1117C>T SNP proved to be responsible for a substantial portion of the inter-individual variability in the pharmacokinetics of YM-64227.


Key words: CYP1A, genetic polymorphism, in vitro-in vivo scaling


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
D. Tenmizu, K. Noguchi, and H. Kamimura
Elucidation of the Effects of the CYP1A2 Deficiency Polymorphism in the Metabolism of 4-Cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1H)-one (YM-64227), a Phosphodiesterase Type 4 Inhibitor, and Its Metabolites in Dogs
Drug Metab. Dispos., November 1, 2006; 34(11): 1811 - 1816.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.